Immunoglobulin G and subclasses in COPD exacerbator phenotype: levels in exacerbation time and clinical stability
| Autor: | Anna Serrano Fores, Elisabet Palomera Fanegas, Isabel Moreno Hernández, Maria Bartolomé Regué, Jordi Juanola Pla, Jordi Almirall Pujol, Ainhoa Montero Rodriguez, Mateu Serra Prat, M. Carmen De La Torre Terron, Ramon Boixeda Viu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Thorax
COPD education.field_of_study medicine.medical_specialty Exacerbation medicine.diagnostic_test biology medicine.drug_class business.industry Antibiotics Population medicine.disease Immunoglobulin G Internal medicine medicine biology.protein Blood test Cortisone education business medicine.drug |
| Zdroj: | Allergy and immunology. |
| Popis: | Purpose: To determinate the Immunoglobulin G level and its subclasses in COPD exacerbator phenotype in exacerbation time and to evaluate those levels in clinical stability in same patients Methods: Prospective observational population-based study. COPD patients who consulted for an exacerbation in 3 health centers or referral hospital were included. During the visit they were classified into 2 groups (exacerbators (E) or non-exacerbators (NE)), defined as exacerbators if they had ≥2 exacerbations in the last year. A clinical questionnaire, blood test with determination of IgG and subclasses and thorax radiography was performed. In clinical stability, after 6 months of exacerbation amb minimal one free month of cortisone and antibiotics, new blood test with determination of IgG and subclasses, in both groups (E/NE), was performed. Results: From November 2016 to March 2019, 295 patients (E: 150, NE: 145) were included: male gender 79.5%, average age 72.2 years (43-94 years). The post-bronchodilator FEV1 55.7% (10-96), considered moderate COPD. Leukocytes 11,965 mm/103uL (2,800-27,760). IgG level in E was in exacerbation 772g/dl vs 877g/dl in stability (p 0.001). IgG level in NE was in exacerbation 862.8g/dl vs 949.4g/dl in stability (p The other relevant results of Ig tests are in next tables: Conclusions: Patients with an exacerbator phenotype have lower levels of IgG. Both groups have lower levels in exacerbation time and its recovered in clinical stability. Clinical Implications These results could open a new path by considering the administration of Ig as a possible treatment in these patients to prevent exacerbations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|